Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 466

1.

Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?

Papanas N, Maltezos E.

Curr Pharm Des. 2009;15(27):3179-92. Review.

PMID:
19754390
2.

Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents.

Granberry MC, Fonseca VA.

Am J Cardiovasc Drugs. 2005;5(3):201-9. Review.

PMID:
15901207
3.

A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.

Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA.

Am Heart J. 2007 Mar;153(3):445.e1-6.

PMID:
17307426
4.

Treatment of diabetes mellitus: implications of the use of oral agents.

Rao SV, Bethel MA, Feinglos MN.

Am Heart J. 1999 Nov;138(5 Pt 1):S334-7. Review. No abstract available.

PMID:
10539794
5.

Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.

Pfützner A, Forst T.

Expert Opin Pharmacother. 2006 Mar;7(4):463-76. Review.

PMID:
16503818
6.

A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering.

Ginsberg H, Plutzky J, Sobel BE.

J Cardiovasc Risk. 1999 Oct;6(5):337-46. Review.

PMID:
10534139
7.

Oral antidiabetic agents as cardiovascular drugs.

Macfarlane DP, Paterson KR, Fisher M.

Diabetes Obes Metab. 2007 Jan;9(1):23-30. Review.

PMID:
17199715
8.

[Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease].

Nauck MA, Matthaei S.

Dtsch Med Wochenschr. 2005 Apr 29;130(17):1091-6. Review. German. No abstract available.

PMID:
15841424
9.

The anti-atherogenic effects of thiazolidinediones.

Stojanovska L, Honisett SY, Komesaroff PA.

Curr Diabetes Rev. 2007 Feb;3(1):67-74. Review.

PMID:
18220657
10.

Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.

Pfützner A, Weber MM, Forst T.

Expert Opin Pharmacother. 2007 Aug;8(12):1985-98. Review.

PMID:
17696799
11.

Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.

Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R Sr, Kondos GT, Perez A, Chen Z, Mazzone T.

Circulation. 2008 Apr 22;117(16):2123-30. doi: 10.1161/CIRCULATIONAHA.107.746610. Epub 2008 Apr 14.

12.

Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.

Fisman EZ, Tenenbaum A, Motro M, Adler Y.

Herz. 2004 May;29(3):290-8. Review.

PMID:
15167955
13.

Pleiotropic effects of thiazolidinediones.

Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS.

Expert Opin Pharmacother. 2008 May;9(7):1087-108. doi: 10.1517/14656566.9.7.1087. Review.

PMID:
18422468
14.

[Oral antidiabetic therapy].

Schneider S, Pazdzierny G, Klein HH.

Dtsch Med Wochenschr. 2006 Dec;131 Suppl 8:S264-7. Review. German.

PMID:
17139584
15.

Effects of pioglitazone on lipid and lipoprotein metabolism.

Betteridge DJ.

Diabetes Obes Metab. 2007 Sep;9(5):640-7. Review.

PMID:
17697057
16.

Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA).

Karamanos B, Thanopoulou A, Drossinos V, Charalampidou E, Sourmeli S, Archimandritis A; Hellenic ECLA Study Group.

Curr Med Res Opin. 2011 Feb;27(2):303-13. doi: 10.1185/03007995.2010.542081. Epub 2010 Dec 9.

PMID:
21142615
17.

Metformin therapy and clinical uses.

Scarpello JH, Howlett HC.

Diab Vasc Dis Res. 2008 Sep;5(3):157-67. doi: 10.3132/dvdr.2008.027. Review.

PMID:
18777488
18.

Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.

Forst T, Hohberg C, Fuellert SD, Lübben G, Konrad T, Löbig M, Weber MM, Sachara C, Gottschall V, Pfützner A.

Horm Metab Res. 2005 Aug;37(8):521-7.

PMID:
16138267
19.

Effects of thiazolidinediones beyond glycaemic control.

Kalaitzidis RG, Sarafidis PA, Bakris GL.

Curr Pharm Des. 2009;15(5):529-36. Review.

PMID:
19199979
20.

The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.

Polonsky T, Mazzone T, Davidson M.

Trends Cardiovasc Med. 2009 Apr;19(3):94-9. doi: 10.1016/j.tcm.2009.06.002. Review.

PMID:
19679266

Supplemental Content

Support Center